Targeted cancer therapy

Nature

Volumn 432, Issue 7015, 2004, Pages 294-297

  Sawyers, Charles ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; MOLECULES; SIGNAL PROCESSING;

COMPLEX NETWORKS; REGULATORY FACTORS; THERAPY;

TUMORS;

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; BEVACIZUMAB; CEP 701; DASATINIB; EVEROLIMUS; GEFITINIB; IMATINIB; MIDOSTAURIN; SORAFENIB; SU 01248; TEMSIROLIMUS; UNCLASSIFIED DRUG;

CANCER;

CANCER; CANCER THERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DERMATOFIBROSARCOMA PROTUBERANS; DNA DAMAGE; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; HUMAN; HUMAN CELL; LUNG CANCER; ONCOGENE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POINT MUTATION; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION; TARGETED CANCER THERAPY; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 9244222261     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03095     Document Type: Review

References (31)

1. Sawyers, C. L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17, 2998-3010 (2003).
2. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
3. Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
4. Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004).
5. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
6. Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949-950 (2003).
7. Samuels, Y. et al. High frequency of mutations of the PTK3CA gene in human cancers. Science 304, 554 (2004).
8. Cools, J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIPILI genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214 (2003).
9. Rubin, B. P. et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20,3586-3591 (2002).
10. De Angelo, D. J. et al. Phase I clinical results with MLN518, a novel FLT3 antagonist: tolerability, pharmacokinetics, and pharmacodynamics. Blood 102 (65a), Abstr. 219 (2003).
11. Stone, R. M. et al. Oral PKC 412 has activity in patients (pts) with mutant FLT3 acute myeloid leukemia (AML): a phase II trial. Proc. Am. Soc. Clin. Oncol. Abstr. 22, 563 (2003).
12. Smith, B. D. et al, Single agent CEP-701, a novel FLT3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Proc. Am. Soc. Clin. Oncol. Abstr. 22, 194 (2003).
13. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
14. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
15. Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475 (2002).
16. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
17. Romer, J. T. et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptcl(-/-)p53(-/-) mice. Cancer Cell 6, 229-240 (2004).
18. Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995).
19. Williams, M. E., Swerdlow, S. H. & Meeker, T. C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 7, 1437-1440 (1993).
20. Sawyers, C. L. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4, 343-348 (2003).
21. Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).
22. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to ST1571 in vitro. Blood 99, 319-325 (2002).
23. Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003).
24. Chu, S. et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatimb mesylate treatment. Blood published online 2 September 2004 (doi: 10.1182/blood-2004-03-1114).
25. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
26. Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl J. Med. 349, 427-434 (2003).
27. Ratain et al. ASCO annual meeting proceedings (post-meeting edn). J. Clin. Oncol. 22, (no. 14 suppl.) 4501 (2004).
28. Motzer et al. ASCO annual meeting proceedings (post-meeting edn). J. Clin. Oncol. 22, (no. 14 suppl.) 4500 (2004).
29. Kaelin, W. G., Jr Molecular basis of the VHL hereditary cancer syndrome. Nature Rev. Cancer 2, 673-682 (2002).
30. Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004).
31. Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011 (1999).